Join
Live feed
·
PRReleasevia Quantisnow
XOMA Royalty Corporation logo

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

ByQuantisnow·Wall Street's wire, on your screen.
XOMA· XOMA Royalty Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XOMA (XOMA Royalty Corporation) and more on Quantisnow.